Literature DB >> 11818530

Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice.

Mingjian James You1, Diego H Castrillon, Boris C Bastian, Rónán C O'Hagan, Marcus W Bosenberg, Ramon Parsons, Lynda Chin, Ronald A DePinho.   

Abstract

Dual inactivation of PTEN and INK4a/ARF tumor suppressor genes is a common feature observed in a broad spectrum of human cancer types. To validate functional collaboration between these genes in tumor suppression, we examined the biological consequences of Pten and/or Ink4a/Arf deficiency in cells and mice. Relative to single mutant controls, Ink4a/Arf-/-Pten+/- mouse embryonic fibroblast cultures exhibited faster rates of growth in reduced serum, grew to higher saturation densities, produced more colonies upon low density seeding, and showed increased susceptibility to transformation by oncogenic H-Ras. Ink4a/Arf deficiency reduced tumor-free survival and shortened the latency of neoplasias associated with Pten heterozygosity, specifically pheochromocytoma, prostatic intraepithelial neoplasia, and endometrial hyperplasia. Compound mutant mice also exhibited an expanded spectrum of tumor types including melanoma and squamous cell carcinoma. Functional synergy between Ink4a/Arf and Pten manifested most prominently in the development of pheochromocytoma, prompting an analysis of genes and loci implicated in this rare human neoplasm. The classical pheochromocytoma genes Ret, Vhl, and Nf-1 remained intact, a finding consistent with the intersection of these genes with pathways engaged by Pten and Ink4a/Arf. Notably, conventional and array-comparative genomic hybridization revealed frequent loss of distal mouse chromosome 4 in a region syntenic to human chromosome 1p that is implicated in human pheochromocytoma. This study provides genetic evidence of collaboration between Pten and Ink4a/Arf in constraining the growth and oncogenic transformation of cultured cells and in suppressing a wide spectrum of tumors in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11818530      PMCID: PMC122212          DOI: 10.1073/pnas.022632099

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.

Authors:  X P Zhou; O Gimm; H Hampel; T Niemann; M J Walker; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma.

Authors:  O Gimm; M Armanios; H Dziema; H P Neumann; C Eng
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

3.  Sporadic and familial pheochromocytomas are associated with loss of at least two discrete intervals on chromosome 1p.

Authors:  D E Benn; T Dwight; A L Richardson; L Delbridge; C P Bambach; M Stowasser; R D Gordon; D J Marsh; B G Robinson
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

4.  PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways.

Authors:  L Weng; J Brown; C Eng
Journal:  Hum Mol Genet       Date:  2001-02-01       Impact factor: 6.150

Review 5.  The von Hippel-Lindau tumor suppressor gene.

Authors:  K Kondo; W G Kaelin
Journal:  Exp Cell Res       Date:  2001-03-10       Impact factor: 3.905

Review 6.  PTEN: life as a tumor suppressor.

Authors:  L Simpson; R Parsons
Journal:  Exp Cell Res       Date:  2001-03-10       Impact factor: 3.905

7.  Dual inactivation of RB and p53 pathways in RAS-induced melanomas.

Authors:  N Bardeesy; B C Bastian; A Hezel; D Pinkel; R A DePinho; L Chin
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

8.  Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer.

Authors:  N Burri; P Shaw; H Bouzourene; I Sordat; B Sordat; M Gillet; D Schorderet; F T Bosman; P Chaubert
Journal:  Lab Invest       Date:  2001-02       Impact factor: 5.662

Review 9.  DNA copy number losses in human neoplasms.

Authors:  S Knuutila; Y Aalto; K Autio; A M Björkqvist; W El-Rifai; S Hemmer; T Huhta; E Kettunen; S Kiuru-Kuhlefelt; M L Larramendy; T Lushnikova; O Monni; H Pere; J Tapper; M Tarkkanen; A Varis; V M Wasenius; M Wolf; Y Zhu
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

10.  Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse.

Authors:  A Di Cristofano; M De Acetis; A Koff; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  2001-02       Impact factor: 38.330

View more
  34 in total

Review 1.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 2.  Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

Authors:  Janice M Mehnert; Harriet M Kluger
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

3.  FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis.

Authors:  Ji-Hye Paik; Ramya Kollipara; Gerald Chu; Hongkai Ji; Yonghong Xiao; Zhihu Ding; Lili Miao; Zuzana Tothova; James W Horner; Daniel R Carrasco; Shan Jiang; D Gary Gilliland; Lynda Chin; Wing H Wong; Diego H Castrillon; Ronald A DePinho
Journal:  Cell       Date:  2007-01-26       Impact factor: 41.582

Review 4.  Growth factors and oncogenes as targets in melanoma: lost in translation?

Authors:  Lawrence Kwong; Lynda Chin; Stephan N Wagner
Journal:  Adv Dermatol       Date:  2007

Review 5.  Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis.

Authors:  Charlotte Lussey-Lepoutre; Alexandre Buffet; Aurélie Morin; Judith Goncalves; Judith Favier
Journal:  Cell Tissue Res       Date:  2018-02-09       Impact factor: 5.249

6.  Arf tumor suppressor promoter monitors latent oncogenic signals in vivo.

Authors:  Frederique Zindy; Richard T Williams; Troy A Baudino; Jerold E Rehg; Stephen X Skapek; John L Cleveland; Martine F Roussel; Charles J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-09       Impact factor: 11.205

7.  Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis.

Authors:  C Nogueira; K-H Kim; H Sung; K H T Paraiso; J-H Dannenberg; M Bosenberg; L Chin; M Kim
Journal:  Oncogene       Date:  2010-08-16       Impact factor: 9.867

Review 8.  Genetically engineered mouse models of prostate cancer.

Authors:  Maxime Parisotto; Daniel Metzger
Journal:  Mol Oncol       Date:  2013-02-14       Impact factor: 6.603

9.  Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by IκB kinase α (IKKα).

Authors:  Han C Dan; Aaron Ebbs; Manolis Pasparakis; Terry Van Dyke; Daniela S Basseres; Albert S Baldwin
Journal:  J Biol Chem       Date:  2014-07-02       Impact factor: 5.157

Review 10.  Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Authors:  Hilde Dannenberg; Paul Komminoth; Winand N M Dinjens; Ernst Jan M Speel; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.